Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression - PubMed (original) (raw)
Clinical Trial
. 2012 Dec;159(5):608-12.
doi: 10.1111/bjh.12077. Epub 2012 Oct 9.
- PMID: 23043283
- DOI: 10.1111/bjh.12077
Free article
Clinical Trial
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression
Sandra Eketorp Sylvan et al. Br J Haematol. 2012 Dec.
Free article
No abstract available
Similar articles
- Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A, Lundin J. Winqvist M, et al. Cancer Immunol Immunother. 2017 Jan;66(1):91-102. doi: 10.1007/s00262-016-1922-6. Epub 2016 Nov 4. Cancer Immunol Immunother. 2017. PMID: 27815572 Free PMC article. Clinical Trial. - Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
Hill BT, Caimi P, Kindwall-Keller T, Habecker B, Kalaycio M. Hill BT, et al. Br J Haematol. 2014 Jan;164(2):297-9. doi: 10.1111/bjh.12604. Epub 2013 Oct 17. Br J Haematol. 2014. PMID: 24131326 No abstract available. - Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K, Mertens D, Stilgenbauer S. Giannopoulos K, et al. Expert Opin Pharmacother. 2011 Dec;12(18):2857-64. doi: 10.1517/14656566.2011.635644. Expert Opin Pharmacother. 2011. PMID: 22098228 Review. - Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.
Pitini V, Cascio A, Arrigo C, Altavilla G. Pitini V, et al. Br J Haematol. 2012 Jan;156(1):1. doi: 10.1111/j.1365-2141.2011.08802.x. Epub 2011 Jul 25. Br J Haematol. 2012. PMID: 21790529 No abstract available. - Monoclonal antibodies in chronic lymphocytic leukemia.
Ferrajoli A, Faderl S, Keating MJ. Ferrajoli A, et al. Expert Rev Anticancer Ther. 2006 Sep;6(9):1231-8. doi: 10.1586/14737140.6.9.1231. Expert Rev Anticancer Ther. 2006. PMID: 17020457 Review.
Cited by
- Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A, Lundin J. Winqvist M, et al. Cancer Immunol Immunother. 2017 Jan;66(1):91-102. doi: 10.1007/s00262-016-1922-6. Epub 2016 Nov 4. Cancer Immunol Immunother. 2017. PMID: 27815572 Free PMC article. Clinical Trial. - The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells.
Saulep-Easton D, Vincent FB, Quah PS, Wei A, Ting SB, Croce CM, Tam C, Mackay F. Saulep-Easton D, et al. Leukemia. 2016 Jan;30(1):163-72. doi: 10.1038/leu.2015.174. Epub 2015 Jul 3. Leukemia. 2016. PMID: 26139429 Free PMC article. - Trial Watch: Lenalidomide-based immunochemotherapy.
Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Semeraro M, et al. Oncoimmunology. 2013 Nov 1;2(11):e26494. doi: 10.4161/onci.26494. Epub 2013 Oct 21. Oncoimmunology. 2013. PMID: 24482747 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources